UndisclosedStrategic acquisitionHealthcare & Life SciencesCompleted
Dechra completes acquisition of pet stem-cell biotech Gallant
Dechra, a global veterinary specialty care company, completed its purchase of Gallant Pet, a U.S. animal-health biotech pioneering ready-to-use mesenchymal stromal cell therapies, marking its expansion into regenerative medicine. Terms were not disclosed.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →